SamanTree Medical Raises $14M in Series B Financing Round to Support Global Expansion and Innovation in Surgical Treatment
Summary
SamanTree Medical Raises $14M in Series B Financing Round to Support Global Expansion and Innovation in Surgical TreatmentHenry Charlton and Claire Poulard to join the Board of DirectorsFunding will Accelerate US Market Entry, Enhance Digital Solutions, and Support Clinical DevelopmentsSamanTree Medical, a leading medical technology company specializing in innovative solutions to improve the outcomes of surgery, today announced the closing of $14M as part of a Series B financing round. The new capital will be used to further develop and commercialize the Histolog\xae Scanner, expand its reach in Europe and the United States, and enhance its digital suite.The Histolog Scanner, a CE-marked device, allows for high-resolution imaging of fresh tissue surfaces during surgery, enabling pathologists and surgeons to perform real-time intra-operative assessment of resected tissue much faster than the conventional techniques. The new Board composition is as follows:CEO Olivier Delporte explained: We are elated by the robust support from our investors, which highlights SamanTree Medicals impressive progress. This funding, coupled with our strengthened Board, will enable us to accelerate our innovation, expand globally, and enhance our digital solutions, thereby delivering greater value to patients. The Histolog Scanner is a potentially significant advancement that provides surgeons with real-time actionable information to their decision-making, said Henry Charlton, SVP and Chief Commercial Officer at Intuitive.As part of the financing conditions, SamanTree Medical is set to expand its commercial operations in Europe and is planning for US market entry later in 2024.